

## Characterising Long Covid: a living systematic review update with controlled studies

**Authors:** Melina Michelen,<sup>1,2</sup> Louise Sigfrid<sup>2</sup>, Christiana Kartsonaki<sup>3</sup>, Ian Shemilt<sup>4</sup>, Claire Hastie<sup>5</sup>, Margaret E. O'Hara<sup>5</sup>, Jake C. Suett<sup>6</sup>, Elisabeth A. Stelson<sup>7,8</sup>, Polina Bugaeva<sup>9</sup>, Dania T. Dahmash<sup>2</sup>, Ishmeala Rigby<sup>2</sup>, Daniel Munblit<sup>10,11,12</sup>, Eli Harriss<sup>13</sup>, Amanda Burls<sup>1</sup>, Vincent Cheng<sup>14</sup>, Janet T. Scott<sup>15</sup>, Gail Carson<sup>2</sup>, Piero Olliaro<sup>2</sup>, Charitini Stavropoulou<sup>1</sup>

1. School of Health and Psychological Sciences, City, University of London, London, UK
2. ISARIC Global Support Centre, Pandemic Sciences Institute, University of Oxford, Oxford, UK
3. Medical Research Council Population Health Research Unit (MRC PHRU), Nuffield Department of Population Health, University of Oxford, Oxford, UK
4. EPPI-Centre, UCL Social Research Institute, University College London, London, UK
5. Long Covid Support, London, UK
6. Queen Elizabeth Hospital, Kings Lynn, UK
7. Harvard T.H. Chan School of Public Health, Department of Social & Behavioral Sciences, Massachusetts, USA
8. Patient Led Research Collaborative, Washington DC, USA
9. Julius-Maximilians-Universität Würzburg, Würzburg, Germany
10. Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
11. Inflammation, Repair and Development Section, National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, UK
12. Research and Clinical Center for Neuropsychiatry, Moscow, Russia
13. Bodleian Health Care Libraries, University of Oxford, Oxford, UK
14. Bristol Medical School, University of Bristol, Bristol, UK
15. MRC-University of Glasgow Centre for Virus Research, Glasgow, UK

Correspondence to [C.Stavropoulou@city.ac.uk](mailto:C.Stavropoulou@city.ac.uk)

### **Section 1: What is already known?**

- Published evidence indicates a high prevalence of people affected by post-acute SARS-CoV-2 sequelae often referred to as Long Covid; yet these estimates are impacted by heterogeneity in study design and a lack of controlled studies and core outcome sets.
- Our first version of this review, looking at studies till March 2021, identified a breadth of reported symptoms of Long Covid affecting both those who were hospitalised during the acute phase and those managed in the community. We also identified a lack of studies including children and set in low-middle income countries.
- The most commonly reported symptoms identified were weakness, general malaise, fatigue, concentration difficulties, and breathlessness, suggesting Long Covid is a complex, heterogeneous condition.

### **Section 2: What are the new findings?**

- To address the limitations identified, this first update of our 'living' systematic review provides a comprehensive summary of peer-reviewed published studies with a control group (till 22<sup>nd</sup> February 2022) on the risk of experiencing Covid-19 sequelae.
- Despite study limitations identifying control groups, our findings suggest that people with a confirmed previous SARS-CoV-2 infection are 1.5 times more likely to experience new or persisting symptoms at 12 or more weeks post-onset when compared to a control group.
- Mapped to the new Core Outcome set for Post-Covid-19 Condition, a framework for standardised assessment, our review identifies cardiovascular functioning, cognitive functioning, and physical functioning as the outcomes with highest increased risk for people post-SARS-CoV-2 infection compared to controls.

### **Section 3: What do the new findings imply?**

- Our findings point to a clear association between exposure to SARS-CoV-2 and the risk of developing new or persistent symptoms, for some lasting longer than 12 months after the initial infection.
- Controlled studies on Long Covid should focus on improving quality to enable multisite meta-analysis by using standardised research protocols and by evaluating participants with multiple standardised diagnostic tests at various time points to capture transitory and intermittent symptoms and complications.
- To help inform health system planning and rehabilitation to improve outcomes for those

affected, Long Covid research should focus on estimating the burden of post-acute SARS-CoV-2 in lower resourced settings, investigating the impact of vaccination and variants on Long Covid, and investigating therapeutic strategies.

WITHDRAWN  
see manuscript DOI for details

## ABSTRACT

**Background:** The clinical sequelae (Long Covid) of acute Covid-19 are recognised globally, yet the risk of developing them is unknown.

**Methods:** A living systematic review (second version). Bibliographical records from the C19 Living Map Long Covid 'segment' (22nd February 2022), Medline, CINAHL, Global Health, WHO Covid-19 database, LitCOVID, and Google Scholar (18th November 2021). We included studies with at least 100 people at 12 weeks or more post-Covid-19 onset and with a control group without confirmed Covid-19. Risk of bias was assessed using the Newcastle-Ottawa scale. Symptoms are aligned with the Post Covid-19 Condition Core Outcome Set. We present descriptive statistics and use meta-analysis to estimate the relative risk of experiencing Long Covid.

**Results:** Twenty-eight studies were included: 20 cohort, five case-controls, three cross-sectional. Studies reported on 242,715 people with Covid-19 (55.6% female) and 276,317 controls (55.7% female) in 16 countries. Most were of moderate quality (71%). Only two were set in low-middle-income countries and few included children (18%). The longest mean follow-up time was 419.8 (standard deviation 49.4) days post-diagnosis. The relative risk (RR) of experiencing persistent or new symptoms in cases compared with controls was 1.53 (95% CI: 1.50 to 1.56). The core outcomes with the highest increased risk were cardiovascular (RR 2.53 95% CI: 2.16 to 2.96), cognitive (RR 1.99; 95% CI: 1.82 to 2.17), and physical functioning (RR 1.85; 95% CI: 1.75 to 1.96).

**Conclusion:** SARS-CoV-2 infection is associated with a higher risk of new or persistent symptoms when compared with controls that can last over a year following acute Covid-19. There is still a lack of robust studies set in lower resourced settings and current studies have high heterogeneity and potential misclassifications of cases and controls. Future research should explore the role of vaccination and different variants on the risk of developing Long Covid.

**Systematic review registration** The protocol was prospectively registered on the PROSPERO database (CRD42020211131).

**Keywords:** Covid-19, SARS-CoV-2, Long Covid, SARS-CoV-2 sequelae, post-acute Covid-19, meta-analysis, control studies, physical and psychological symptoms

WITHDRAWN  
see manuscript DOI for details

## INTRODUCTION

A wide range of persistent and new symptoms and complications following Covid-19, termed Long Covid by those with lived experience of the disease [1], have been reported worldwide.[2] The World Health Organisation (WHO) proposed the term 'Post COVID-19 condition' and defined it as a condition occurring in individuals with a history of probable or confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection three months from the onset of Covid-19 that last for at least two months and cannot be explained by an alternative diagnosis.[3] While many terms are being used interchangeably by researchers, clinicians, and health authorities, [2] this review refers to the National Institute for Health and Care Excellence (NICE) definition of a syndrome continuing for over 12 weeks and the Long Covid term, as agreed by many patient groups and in recognition of their progress made using this term.[4]

Estimates on Long Covid prevalence also vary across studies. The WHO estimated that approximately 10-20% of people who develop Covid-19 experience symptoms lasting much longer than the initial phase of the illness.[5] Some studies suggest the risk of Long Covid may be reduced with vaccination,[6,7] yet, despite high vaccination rates [8,9], this still translates into millions of people experiencing Long Covid given the wide spread of Covid-19 worldwide.[10]

Since the publication of the first version of this living systematic review (LSR) [11], published evidence on Long Covid has increased exponentially, making the need for a living systematic review more apparent than ever. There have been more studies on Long Covid in the community, studies with a longer follow-up, and more studies that include a control group in their analysis. Further, a number of developments have allowed us to enhance the methodological process for this current version and future updates. First, we established a collaboration with the Evidence for Policy and Practice Information and Co-ordinating Centre (EPPI) Centre, to deploy and evaluate [12] a novel semi-automated study identification workflow, incorporating a direct supply of records from the

Long Covid 'segment' of a living systematic map of Covid-19 research [13] and machine learning tools, for efficient updating of this review. Second, knowledge around the outcomes of Long Covid has progressed and the development of a Post-Covid Core Outcomes Set (COS) [14] allows us to focus on the symptoms that have been selected as the most important in a Delphi consensus process by patients, clinicians, and researchers in the area. These developments will allow for reporting of more relevant results and for the process of conducting future updates to be more efficient and timely.

## **METHODS**

The findings of many systematic reviews conducted early during the Covid-19 pandemic had the potential to quickly become outdated due to the unprecedented rapid pace of evolution and publication of new primary research on Covid-19. In recognition of this, we followed a 'living systematic review' (LSR) approach, developed for the regular updating of reviews to incorporate emerging data from new eligible studies, in rapidly evolving areas of research.[15,16]

This is the second version of a LSR that provides evidence on the symptoms and complications of Long Covid, developed in collaboration with infectious disease clinicians, public health professionals, information specialists, review methodologists with experience in clinical epidemic research, and people with lived experience of Long Covid. It will be updated approximately every 12 months as new evidence emerges, using the established protocol and review platform. Previous versions will be archived in the supplementary materials.

In this second version, we followed the strategy described in our protocol [17] to identify studies that met the study's criteria. Yet, and given the evolving landscape on Long Covid and our knowledge around it, we focused our analysis not on summarising the prevalence of different symptoms as we did in the first version, but on the quantifying the relative risk of developing Long Covid. Hence our

analysis for this version focuses on only the studies with control groups as explained in further detail below.

Crucial to this version has been the attempt to methodologically improve the way we can identify and update our searches, linking our study to EPPI's living maps.[18] A study within a review (SWAR) has been conducted alongside this update and will be published as a separate paper presenting the details of how this was done.[12]

### **Protocol registration**

This report is structured according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines (see PRISMA flowchart in supplement 1).[19] The protocol was registered with PROSPERO (CRD42020211131) and published in a peer-reviewed journal.[17]

### **Search strategy**

Bibliographic records were supplied directly from the C19 Living Map Long Covid 'segment' (18th March to 25th October 2021) [13], which is being continuously maintained using automated searches of the OpenAlex dataset – an open access repository containing records of >250 research articles from across science [20]. We also searched Medline and CINAHL (EBSCO), Global Health (Ovid), and the WHO Covid-19 database (18th March to 18th November 2021); and the LitCOVID register's Long Covid 'segment' (18th March to 17th November 2021). Additionally, we searched Google Scholar on 17th November 2021, screening the first 500 titles. Full search strategies are included in supplement 2. Finally, we updated our search with a direct supply of records from the C19 Living Map Long Covid 'segment' (26th October 2021 to 22nd February 2022). As such, the date of the last search conducted for this LSR version was 22nd February 2022.

### **Eligibility criteria**

Peer-reviewed studies were considered eligible if they included at least 100 people with laboratory confirmed and/or clinically diagnosed Covid-19. We included studies that reported symptoms or outcomes assessed at an average of 12 or more weeks post Covid-19 onset [3]. There were no language restrictions. Reviews and opinion pieces were excluded. Studies were excluded if they included fewer than 100 participants, to avoid small study effects,[21] or the follow-up was unclear or less than 12 weeks post-onset. As Long Covid symptoms have been well categorised in a number of studies and reviews,[11,22–24] this second version focuses on addressing some urgent, remaining research priorities focusing on controlled studies comparing those with evidence of confirmed Covid-19 to those without, including untested, those testing negative, and historical cohorts.

### **Study selection**

Screening was performed independently by two systematic reviewers using a two-stage process, first screening titles and abstracts and then the full text of selected studies. Both stages were managed using a semi-automated workflow and machine learning tools hosted in EPPI Reviewer web-based software for evidence synthesis (ER-Web) [25]. Study selection methods including title abstract and full text screening are described in further details in supplement 3. Any disagreements were resolved via consensus or a third reviewer. Non-English records (and/or corresponding full-texts) were translated using Google Translate and assessed by a systematic reviewer with good knowledge of the original publication language.

### **Data extraction and analysis**

Data extraction was performed by one systematic reviewer and checked by a second reviewer using an updated Microsoft Excel template informed by a previous review [11]. Disagreements were

resolved through consensus or involvement of a third reviewer. Data extracted included study design, setting, population characteristics for both the Covid-19 and control population (sample sizes, description, age, gender), Covid-19 confirmation methods and severity, follow-up time and methods, and outcomes prevalence and risk ratios. To ensure standardised data reporting and uniformity in Long Covid clinical research, outcomes were grouped into physiological clusters using an existing taxonomy by Dodd and colleagues [26], through discussions with clinicians, and following the rigorous development of an international consensus-based core outcome set (COS) for post-covid condition [14]. This COS includes 12 outcomes: fatigue; pain; post-exertion symptoms; work or occupational and study changes; survival; and functioning, symptoms, and conditions for each of cardiovascular, respiratory, nervous system, cognitive, mental health, and physical outcomes, as well as recovery. As this COS is intended for adults, and with the emergence of more studies in children, other signs and symptoms were included to ensure outcomes of importance to other groups are not overlooked [27].

The data is presented using a combination of descriptive statistics, forest plots, and tables as well as infographics, prepared by a design company (Design Science [28]) to facilitate interpretation by different stakeholders, including non-specialists.

### ***Risk of bias assessment***

The methodological quality of included studies was assessed independently by two investigators using the Newcastle-Ottawa Scale (NOS) tool [29]; any disagreements were resolved via consensus. The NOS evaluation includes a “star system” across three domains: the selection of cohorts, the comparability of the study groups, and the ascertainment of exposure or outcomes, with a maximum score of four, two, and three stars, respectively. A total score from zero to nine is assigned per study, and studies with scores  $\geq 7$  were considered of low risk of bias, scores between 4 to 6 medium risk, and scores under 4 high risk.

### **Statistical analysis**

Relative risks (RR) and their 95% confidence intervals (CIs) were calculated from the number of people reporting each individual outcome among those with and without Covid-19. For outcomes with data from two or more studies, an inverse-variance weighted meta-analysis was performed. Heterogeneity between estimates was assessed using Cochran's Q test and the percentage of variation across studies that is due to heterogeneity rather than chance using the  $I^2$  statistic [30]. An additional prespecified subgroup analysis was done to assess whether there were any differences in associations with each outcome by setting (community, hospitalised, mixed). A prespecified sensitivity analysis was conducted in which studies with a high risk of bias were excluded to examine their impact on the estimates. All analysis was done using R version 4.1.3 and packages 'meta', 'tidyverse' and 'ckbplotr'. [31]

### **Patient and public involvement**

The study team includes members who have been affected by long term Covid-19 sequelae, including members of Long Covid Support [32], a patient-led UK based charity with global reach, that provides support to approximately 53,000 people through its online support forums. They actively contributed to develop the study protocol, inform the research questions, interpret and present findings, and to communicate the results to different audiences. The results of this LSR will be disseminated to Long Covid patient forums for discussion and feedback to inform research priorities and updates.

### **RESULTS**


We retrieved 11,520 records (articles) for potential screening, 289 studies met our criteria, from which 28 studies (reported in 28 separate articles, all published in English) included a control (supplement 1). The full list of studies can be provided upon request. Of these, 22 studies were

included in the meta-analysis. The remaining six studies include imaging and diagnostics, and are presented narratively.

### Characteristics of included studies

Most studies were set in Europe and Central Asia (68%, 19/28), followed by East Asia and Pacific (11%, 3/28), North America (11%, 3/28), Latin America and the Caribbean (4%, 1/28), Middle East and North Africa (4%, 1/28), and South Asia (4%, 1/28) (Figure 1). Only two studies (7%) were set in low-middle income (LMIC) countries [33]. Most were cohort studies (89%, 25/28), followed by cross-sectional studies (11%, 3/28).

Figure 1. Map of study distribution



The map shows the global distribution of the studies identified and the shading shows the combined studies population size by country.

These studies present data on 242,715 people who previously had Covid-19 (55.6% female) and 276,317 controls (56% female) across 16 countries. The majority of studies focused on adults (82%, 23/28) [34–56], while 11% (3/28) included both adults and children [57–59], and 7% (2/28) focused on adolescents [60,61]. Of included studies 46% (13/28) included both hospitalised and non-hospitalised populations, while 29% (8/28) followed up people who were not hospitalised, and 25% (7/28) were cohorts of hospitalised patient post-discharge. Control groups included population testing negative (39.3%, 11/28) [34,39,40,44,46,47,51,55,56,59,61], healthcare workers testing negative (21.4%, 6/28) [35,37,38,42,43,52], historic cohorts (14.3%, 4/28) [45,49,53,58], healthy controls (10.7%, 3/28)[41,48,54], both negative and untested population (7.1%, 2/28) [50,60], and cohorts with influenza (3.5%, 1/28)[57] and sepsis (3.5%, 1/28) [36]. Only 32% (9/28) of studies reported ethnicity of the participants [34,39,41,49,54,56,57,59,61].

The longest follow-up period in any study was a mean of 419.8 (standard deviation: 49.4) days post-diagnosis. Studies followed participants up with various methods, including 50% (14/28) with an outpatient visit consultation [34,36,42,43,46–49,52–55,58], followed by questionnaires, including online (21.4%, 6/28) [37,41,50,51,60,61], phone (14.3%, 4/28) [35,38,40,45], and letter (3.6%, 1/28) [39], while 11% (3/28) used electronic health records (EHRs) data analysis [56,57,59]. Tools used to assess signs and symptoms varied between studies. Tables 1 and 2 present the included study and population characteristics.

**Table 1. Studies characteristics**

Study	Design	Country	Setting	Follow up (days)	Follow up timepoint	Follow-up mode	Tools/methods used
<b>Non-hospitalised</b>							
Berg et al. (2022)	Cross-sectional	Denmark	National	365	Diagnosis	Questionnaire (online)	Ancillary questions and validated questionnaires (Paediatric Quality of Life Inventory [PedsQL], Children's Somatic Symptoms Inventory-24)
Boscolo-Rizzo et al. (2021)	Cohort (P) *	Italy	Regional	Median (IQR) 401 (388-413)	Diagnosis	Questionnaire (phone)	Acute Respiratory Tract Infection Questionnaire; SNOT-22 item "Sense of smell or taste"; WHO-5 questionnaire; VAS; Peak Nasal Inspiratory Flow; Olfactory cleft endoscopy scale; Extended SST
Chevinsky et al. (2021)	Cohort (P)	USA	National	91–120	Diagnosis	Electronic health records	ICD-10 codes
Riestra-Ayora et al. (2021)	Cohort (P) *	Spain	Single centre	182.5	Diagnosis	Questionnaire (phone)	OD/GD VAS
Soraas et al. (2021)	Cohort (P)	Norway	Multi centre	Mean (SD) 132 (35)	Diagnosis	Questionnaire (online)	RAND 36-Item Health Survey; Self-reported symptoms
Soraas et al. (2021) (a)	Cohort (P)	Norway	Multi centre	Mean (SD) 258 (33.9) Mean (SD) 256 (31.9)	Diagnosis	Questionnaire (online)	RAND 36-Item Health Survey; Self-reported memory problems
Stallmach et al. (2022)	Cohort (P)	Germany	Single centre	Median 163 (Q1–Q3 125–203, range 24–552)	Diagnosis	Outpatient visit	Fatigue Assessment Scale; Brief Fatigue Inventory; Depression module of the Patient Health Questionnaire, PHQ-9; Montreal Cognitive Assessment; CFS; Short version of the Brief Symptom Inventory
Stephenson et al. (2022)	Cohort (P)	England	National	104.3	Diagnosis	Questionnaire (online)	ISARIC paediatric COVID-19 questionnaire; Mental Health of Children and Young people in England surveys; Index of Multiple Deprivation; Strengths and Difficulties Questionnaire; 7-item version of the Warwick Edinburgh Mental Wellbeing Scale; EQ-5D-Y ; 11-item CFS
Zamora et al. (2021)	Cohort (P)	Spain	Multi centre	Mean (SD, range) 104 days (21; 64-153)	Diagnosis	Questionnaire (in person)	Barthel index score; FRAIL instrument; Functional Ambulation Classification from Holden; Mini Nutritional Assessment Short Form; Short Portable Mental Status Questionnaire Pfeiffer; 5-item Geriatric Depression Scale from Yesavage; HADS; 8-item Treatment- Outcome Post-Traumatic Stress scale; Insomnia in the Elderly Scale tool

**Hospitalised**

Ayoubkhani et al. (2021)	Cohort (R)	England	Multi centre	Mean (SD) Covid: 140 (50) Controls: 153 (33)	Onset	Electronic health records	ICD-10 codes
Caiado et al. (2021)	Cohort (P)	Brazil	Single centre	Mean (SD) 130.35 (76.06)	Diagnosis	Outpatient visit	2-dimensional speckle-tracking echocardiography
Chevinsky et al. (2021)	Cohort (P)	USA	National	91–120	Discharge	Electronic health records	ICD-10 codes
Huang et al. (2021)	Cohort (A)	China	Single centre	Median (IQR) 349 (337–361)	Onset	Outpatient visit	6-min walking test; Self-reported symptom questionnaire; mMRC dyspnoea scale; EQ-5D-5L; EQ-VAS; Ischaemic stroke and cardiovascular event registration form
Ingul et al. (2022)	Cohort (P)	Norway	Multi centre	Median (range) 102 (70–172)	Discharge	Outpatient visit	Echocardiography; mMRC dyspnoea scale; CFS
Liu et al. (2021)	Cross-sectional	China	Multi centre	182.5	Discharge	Questionnaire (phone)	Telephone interview of Cognitive Status-40; Short form Informant Questionnaire on Cognitive Decline in the Elderly
Vlake et al. (2021)	Cohort (P)	The Netherlands	Single centre	91.25	Discharge	Questionnaire (letter)	Impact of Event Scale-Revised; HADS; EQ-5D; RAND-36 Item Health Survey
Zhou et al. (2021)	Cohort (P)	China	Multi centre	SPs: 128.5 MPs: 125	Onset	Outpatient visit	St. George Respiratory Questionnaire; Lab examination; Chest computed tomography (CT); pulmonary function tests

**Mixed**

Çap et al. (2022)	Cohort (R)	Turkey	Single centre	Median (IQR) 150 (82.5–206.5)	Diagnosis	Outpatient visit	SPECT-MPI
Dennis et al. (2021)	Cohort (P)	UK	Multi centre	Median (IQR) 141 (110–162)	Onset	Outpatient visit	Patient-reported validated questionnaires (quality of life, EQ-5D-5L and Dyspnoea-1227); Organ-specific metrics by biochemical assessment; MRI
Elnaby et al. (2021)	Cohort (P) *	Egypt	Single centre	98 (7.34)	Onset	Outpatient visit	Self-reported
Ghoshal et al. (2021)	Cohort (P) *	Bangladesh India	Multi centre	182.5	NR	Questionnaire (phone)	Hindi and Bengali translated validated Enhanced Asian Rome III Questionnaires and Rome III Psychosocial Alarm Questionnaire
Iversen et al. (2022)	Cohort (P)	Denmark	Regional	Median (IQR) 156.0 (107.8–359.2)	Diagnosis	Outpatient visit	Comprehensive questionnaire and physical health examination including spirometry

Logue et al. (2021)	Cohort (P)	USA	Multi centre	Median (range) 169 (31-300)	Onset	Questionnaire (online)	Questionnaire regarding persistent symptoms, additional medical care, changes in quality of life, and impact on ADLs
Mattioli et al. (2021)	Cohort (P)	Italy	Single centre	126	Diagnosis	Outpatient Visit	MMSE; Controlled Oral Word Association by categories; Rey figure copy and recall; California Verbal Learning Test; TEA attention test; Tower of London test
Noviello et al. (2021)	Cohort (P)	Italy	Single centre	146	Diagnosis	Questionnaire (online)	Structured Assessment of Gastrointestinal Symptoms Scale
Petersen et al. (2022)	Cross-sectional	Germany	Regional	292	Diagnosis	Outpatient visit	Bodyplethysmography (spirometry); Transthoracic echocardiography; MRI; Vascular & Neuroimaging phenotyping; MMSE; Patient Health Questionnaire-9 and -15; Generalized Anxiety Disorder Assessment; EQ-5D; EQ-5D VAS
Taquet et al. (2021)	Cohort (R)	USA	National	90-180	Diagnosis	Electronic health records	ICD-10 codes
Vaira et al. (2021)	Cohort (P) *	Italy Belgium	Multi centre	Mean (SD) 419.8 (49.4)	Diagnosis	Outpatient visit	SST
Willems et al. (2021)	Cohort (P)	The Netherlands	Single centre	Median (range) 114 (50-157)	Recovery	Outpatient visit	Carotid artery reactivity (CAR) test

ADLs: Activities of daily living; APs: Asymptomatic patients; CFS: Chalder Fatigue Scale; EQ-5D-5L: EuroQol five-dimension five-level; GD: Gustatory dysfunction; HADS: Hospital Anxiety and Depression Scale; HCW: Health care worker; ICD-10-CM: Standard International Classification of Diseases, Tenth Revision, Clinical Modification; IQR: inter-quartile range; LTCF: Long term care facility; mMRC: Modified British Medical Research Council; MMSE: Mini-mental state examination; MPs: moderate patients; MRI: magnetic resonance imaging; NR: not reported; OF: Olfactory dysfunction; P: Prospective; R: Retrospective; SD: Standard Deviation; SPECT-MPI: Single-photon emission computed tomography myocardial perfusion imaging; SP: Severe Patients; SST: Sniffin' Sticks test; VAS: Visual Analog Scale

\*Study design derived from manuscript methods, not as stated by author description.

**Table 2. Population characteristics**

Study	Population description	Control description	Population size (Covid/ Control)	Age (Covid/ Control)	Sex (% female) (Covid/ Control)	COVID-19 confirmation (Covid/ Control)
<b>Non-hospitalised</b>						
Berg et al. (2022)	Danish adolescents aged 15–18 years with a positive SARS-CoV-2 test between 1/1/20-12/7/21, identified from the Danish Covid-19 database (LongCOVIDKidsDK)	Matched (1:4) by age and sex, with one or more negative tests during the pandemic and never tested (controls with suspected SARS-CoV-2 at some point but without access to testing were excluded (LongCOVIDKidsDK)	2997 / 21640	Median (IQR) 17.6 (16.5–18.6) / 17.6 (16.4–18.5)	2072 (69.1) / 12404 (57.3)	PCR / PCR & untested
Boscolo-Rizzo et al. (2021)	Home-isolated patients for mildly symptomatic Covid-19 between March and April 2020	Uninfected HCW regularly tested for SARS-CoV-2 infection and always testing negative (PCR), matched by sex and age ( $\pm 3$ years)	100 / 100	Median 49 / Median 49	39 (39) / 39 (39)	PCR / PCR
Chevinsky et al. (2021)	Premier Healthcare Database Special COVID-19 Release (PHD-SR; 20 Oct. 2020), an administrative all-payer database, including inpatient data (922 hospitals) and outpatient data (934 hospitals), with representation in all US Census regions	Using the PHD-SR data, during March–June 2020, patients without COVID-19 were matched on demographics, clinical factors, facility characteristics, and month of index encounter	46857 / 46857	Children 2368 (5%) / 2368 (5%) Adults 44489 (95%) / 44489 (95%)	Children: 1196 (50.5) / 1247 (52.7) Adults: 27225 (61.2) / 27048 (60.8)	ICD-10-CM, discharge codes of U07.1 / Potential controls diagnosed with COVID-19 during the 4 months after index encounter were excluded
Riestra-Ayora et al. (2021)	HCWs from a tertiary care hospital with a high incidence of Covid between March 15- April 7 2020	HCW from same hospital centre testing negative (RT-PCR), matched for age and sex	195 / 125	Mean (range) 41.62 (18–65) / 46.5 (20–64)	156 (80) / 106 (84.8)	RT-PCR / RT-PCR

Soraas et al. (2021)	Adults testing positive (Feb 1- April 15, 2020) in four large accredited laboratories, (excluded later hospitalised)	Adults testing negative (February 1 and April 15, 2020) in four large accredited laboratories	672 / 6006	Mean (SD) 48.5 (13.5) / 46.1 (13)	382 (56.8) / 4520 (75.6)	RT-PCR / RT-PCR
Soraas et al. (2021) (a)	Adults testing positive at 4 large accredited laboratories between February 1 - April 15, 2020	Adults testing negative for SARS-CoV-2 at 4 large accredited laboratories between February 1 and April 15, 2020	651 / 5712	Mean (SD) 48.6 (13.6) / 46.3 (13.0)	369 (57) / 4327 (76)	Lab confirmed / RT-PCR
		Untested adults randomly selected from Norwegian population (nearly all testing during that time was on symptomatic patients /free of charge)	651 / 3342	Mean (SD) 48.6 (13.6) / 52.9 (14.5)	369 (57) / 1768 (53)	Lab confirmed / Untested
Stallmach et al. (2022)	Symptomatic post-COVID patients who visited the out-patient clinic for post-COVID-19 care	Symptomatic patients from the Mid-German Sepsis Cohort with reported potential sepsis sequelae	355 / 272	Median (range) 51 (17–86) / 66 (19–93)	213 (60.0) / 104 (38.2)	Post Covid Clinic / NR
Stephenson et al. (2022)	Adolescents (11–17 years) from the Public Health England database who tested positive for SARS-CoV-2 between January- March, 2021	Adolescents matched by month of test, age, sex, and geographical region who tested negative	3065 / 3739	11–14: 1244 (40.65%) 15–17: 1821 (59.4%) / 11–14: 1609 (43%) 15–17: 2130 (575%)	1945 (63.5) / 2352 (62.9)	RT-PCR / RT-PCR
Zamora et al. (2021)	Residents ≥ 65 years without moderate-to-severe cognitive impairment, living in five LTCFs in Albacete (Spain)	Patients of LTCF with negative Covid-19 test	140 / 75	Median (IQR) 84 (11) / 82 (15)	89 (63.6) / 46 (61.3)	PCR, positive serology, or rapid antigen test / RT-PCR

#### Hospitalised

Ayoubkhani et al. (2021)	The Hospital Episode Statistics Admitted Patient Care records for England up to 31 August 2020 and the General Practice Extraction Service Data for Pandemic Planning and Research (GDPPR) up to 30 September 2020	Individuals in the general population who did not meet the inclusion criteria for covid-19 and had at least one GDPPR record between 1 January 2019- 30 September 2020, matched for baseline personal characteristics and clinical histories	47780 / 47780	Mean (SD) 64.5 (19.2) / <30: 2.5%, 30-49: 18.5%, 50-69: 33.4%, >70: 45.7%	21535 (45.1) / 21535 (45.1)	Positive laboratory test or clinical diagnosis / Lab or clinically confirmed
Caiado et al. (2021)	Patients admitted to the private institution from January 11, 2021, to February 24, 2021 with recovered COVID-19 diagnosed	Healthy patients with no cardiopulmonary diseases according to medical history, physical examination, and electrocardiogram, who underwent echocardiography study as part of routine pre-surgical risk stratification	100 / 100	Mean (SD) 46.93 (15.24) / Mean (SD) 39.17 (9.25)	59 (59) / 50 (50)	PCR (89%), Serological dosage of IgM (16%) , IgG (31%) / NR
Chevinsky et al. (2021)	Patients from the Premier Healthcare Database Special COVID-19 Release (PHD-SR; 20 October 2020), an administrative all-payer database, including inpatient data from 922 hospitals and outpatient data from 934 hospitals, including 269 clinics, with representation in all US Census regions	Using the PHD-SR data, during March–June 2020, patients without COVID-19 were matched on demographics, clinical factors, facility characteristics, and month of index encounter	27589 / 27589	Children 305 (1%) / Adults 27284 (99%) / Children 305 (1%) / Adults 27284 (99%)	Children: 133 (43.6) / Adults: 14313 (52.5) / Children: 136 (44.6) / Adults: 14340 (52.6)	ICD-10-CM discharge codes / Potential controls diagnosed with COVID-19 during the 4 months after their index encounter were excluded
Huang et al. (2021)	Patients discharged from Jin Yin-tan Hospital (Wuhan, China) with lab-confirmed COVID-19	Uninfected community-dwelling adults from two districts of Wuhan city matched for age, sex, and comorbidities	1276 / 1164	Median (IQR) 59.0 (49.0–67.0) / 58.0 (49.0–66.0)	595 (47) / 541 (46)	Lab confirmed / Lab confirmed

Ingul et al. (2022)	Participants in PROLUN (Patient-Related Outcomes and Lung Function After Hospitalization for COVID-19), a prospective cohort study at 6 major hospitals in Norway	Participants in HUNT4 (the fourth wave of the Trøndelag Health Study; 2017–2019), a Norwegian population-based cohort, matched by sex and comorbidity (individually) and age, BMI, and systolic blood pressure (group level)	204 / 204	Mean (SD, Range) 58.5 (13.6, 30–83) / 58.4 (13.4)	90 (44) / 90 (44)	PCR / Historic cohort
Liu et al. (2021)	Inpatients aged over 60 discharged from three COVID-19-designated hospitals in Wuhan, China, from February 10 to April 10, 2020	Uninfected spouses that co-lived with the patients in the same environment confirmed through RT-PCR	1539 / 466	Median (IQR) 69 (66.75) / 67 (66-76)	801 (52.04) / 240 (51.5)	WHO interim guidance / RT-PCR
Vlake et al. (2021)	Patients aged ≥18 years and hospitalized between March 16- April 28, 2020, with symptoms suggestive of COVID-19, and tested positive	Patients aged ≥18 years and hospitalized between March 16 and April 28, 2020, with symptoms suggestive of COVID-19 and tested negative	146 / 148	Median (range) 61 (35-85) / 69 (31-89)	52 (36) / 54 (36)	RT-PCR / RT-PCR
Zhou et al. (2021)	COVID-19 recovered patients from four hospitals between March 5th-31st, 2020 in Wuhan and volunteers who recovered from asymptomatic COVID-19 from an isolation hotel	Community members with no self-reported chronic respiratory disease and both negative SARS-COV-2 nucleic acid and antibody tests, matched for sex and BMI	174 (95 severe/critical (SP), 51 mild/moderate (MP), 28 asymptomatic (AP)) / 42	Median (IQR) SPs: 63 (56-69) MPs: 56 (47-63) APs: 46 (39.5-57) / 46.5 (35.5-56.75)	SPs: 48 (50.5) MPs: 35 (68.6) APs: 16 (57.1) / 22 (52.4)	Nucleic test / Both negative SARS-COV-2 nucleic acid and antibody tests
<b>Mixed</b>						
Çap et al. (2022)	Patients who applied to the cardiology outpatient clinics of our hospital between Jan 1- June 30, 2021, with chest pain and/or shortness of breath and who had undergone SPECT-MPI with a history of Covid 19	Patients who applied to the cardiology outpatient clinics of our hospital between Jan 1 and June 30, 2021, with chest pain and/or shortness of breath and who had undergone SPECT-MPI without a history of Covid-19 (RT-PCR)	329 (36% hospitalised) / 1495	Mean (SD) 55.8 (10.4) / 56.1 (11.5)	220 (67) / 979 (65)	RT-PCR / RT-PCR

Dennis et al. (2021)	Participants recruited through advertisement on social media or via recommendations from clinicians from four participant identification centres	Healthy, age-matched controls	201 (19% hospitalised) / 36	Mean (SD, Range) 44 (11.0, 21-71) / 39 (12.4)	142 (70.6) / 14 (38.9)	RT-PCR (n=62) Positive antibody test (n=63) Clinically diagnosed by two independent clinicians (n=73) / NR
Elnaby et al. (2021)	Medical staff of Bab Al-Sha'reia University Hospital and their relatives, diagnosed 13-16 weeks ago to have COVID-19	Sex, age and BMI matched HCW from the medical staff of the hospital, with no history suggesting COVID-19 infection, tested negative for COVID-19 IgG and IgM by rapid test	103 / 40	Mean (SD) 43.9 (12.99) / 42.97 (9.63)	44 (42.72) / 16 (40)	RT-PCR / No history suggesting COVID-19 infection, tested negative for COVID-19 IgG and IgM by rapid test
Ghoshal et al. (2021)	One cohort from patients in three teaching hospitals during April to August 2020 in Dhaka, Bangladesh, and another cohort diagnosed in a referral laboratory in northern India from outpatient samples obtained from various districts of the State of Uttar Pradesh and the Institute recruited during April- May 2020	6-month follow-up data for IBS and UD development on a cohort of healthy subjects published earlier (August 2014 to February 2016) matching for age and gender	280 / 264	Mean (SD) 39.5 (15.4) / 36.8 (11.6)	76 (27.1) / 71 (27)	RT-PCR / Historic cohort
Iversen et al. (2022)	Adult Copenhagen General Population Study (CGPS) participants with a prepandemic spirometry available	CGPS participants with a prepandemic spirometry available matched by age, sex, ethnicity, and smoking status	107 (11.2% hospitalised) / 499	Mean (SD) 57 (8.7) / 56 (8.4)	57 (53.3) / 265 (53.1)	RT-PCR / RT-PCR
Logue et al. (2021)	Individuals hospitalised at Harborview Medical Center, University of Washington Medical Center, or Northwest Hospital in Seattle, WA, identified through a lab alert system and outpatients at University of Washington clinics or testing positive through the Seattle Flu Study	Healthy controls matched by age, sex, and race recruited through email and flyer advertisements	177 / 21	Mean (SD) 48 (15.2) / 50.8 (15.8)	101 (57.1) / 11 (52.4)	Lab confirmed / NR

Mattioli et al. (2021)	Healthcare workers at University Hospital of Brescia with confirmed diagnosis of COVID-19	HCW matched by age, sex, and BMI from the same hospital who had not been previously affected by COVID-19 (RT-PCR)	120 (1.7% hospitalised) / 30	Median (range) 47.86 (26–65) / 45.73 (23–62)	90 (75) / 22 (73.3)	RT-PCR / RT-PCR
Noviello et al. (2021)	All patients aged between 18 and 60 years who tested positive for SARS-CoV-2 in the laboratories of our hospital between Feb- April 2020	Employees and healthcare professionals who tested negative (RT-PCR) within the surveillance program of the hospital in the same period	164 / 183	Mean (range) 44.1 (23–60) / 39.6 (22–60)	66 (40.2) / 111 (60.7)	RT-PCR / RT-PCR
Petersen et al. (2022)	Adults (45-74 y/o) living in the metropolitan area of Hamburg, Germany, with a lab-confirmed positive PCR test for SARS-CoV-2, obtained between 1 March and 31 December 2020 at least 4 months prior to study enrollment	Adults selected from the population-based Hamburg City Health Study (HCHS) matched for age, sex, and education, enrolled prior to being at risk of infection with SARS-CoV-2 (November–April 2016–19)	443 (7.2% hospitalised) / 1328	Median (IQR) 55 (51–60) / 57 (52–62)	233 (52.6) / 719 (54.1)	PCR / Enrolled prior to being at risk of infection with SARS-CoV-2
Taquet et al. (2021)	Patients with a confirmed COVID-19 diagnosis, over the age of 10 and alive at time of analysis	EHR of propensity score–matched by age, sex, race, ethnicity, and comorbidities patients diagnosed with influenza during same time period (without a diagnosis/ positive test for COVID-19)	106578 / 106578	Mean (SD) 39.4 (18.4) / 38.3 (19.7)	62293 (58.4) / 61419 (57.6)	RNA or antigen testing / No diagnosis or positive test for COVID-19
Vaira et al. (2021)	Consecutive subjects with a confirmed diagnosis of SARS-CoV-2 infection at least 1 year before enrollment	HCW without previous diagnosis (RT-PCR) or suspicion of SARS-CoV-2 infection matched by age and sex	170 / 170	Mean (SD) 39.9 (10.5) / 38.8 (14.1)	100 (58.8) / 100 (58.8)	RT-PCR / RT-PCR
Willems et al. (2021)	Patients who had experienced SARS-CoV-2 infection	Historic cohort from all studies initiated by Radboudumc completing data collection before the pandemic (not affected by COVID-19). Propensity score matched on baseline characteristics and cardiovascular risk profile	203 (64% hospitalised) / 312	Mean (SD) 62.7 (12.4) / 61.1 (15.9)	203 (36.5) / 178 (57.1)	PCR / Historic cohort

### **Risk of bias**


The risk of bias and quality of evidence in individual studies varied, with 17.9% (5/28) of studies assessed as low risk of bias [46,56,57,60,61], 71.4% (20/28) as medium [34–40,42–45,47,49–51,53–55,58,59], and 10.7% (3/28) as high [41,48,52] (supplement 4). The maximum and minimum scores achieved were 3 and 8 points, respectively. The category with the lowest proportion of compliance was ascertainment of outcome, with only 14% (4/28) of studies scoring the maximum score for selection, 36% (10/28) of studies for comparability, and only one study for outcome (4%).

### **Symptoms & signs**

The focus of individual studies in our analysis varied; some authors focused solely on a specialty or a specific symptom making comparative analysis difficult. Even amongst those studies which took a broad approach, the prevalence of symptoms was diverse. Similarly, the prevalence of the more commonly reported symptoms varied markedly. Within these limitations, we performed a meta-analysis of the most commonly reported symptoms and signs of Long Covid. Symptoms were broadly organised according to the COS for the purpose of presentation and interpretation of this review (Figure 2).

Figure 2: Long Covid signs and symptoms

## Long Covid symptoms and signs



A Covid-19 infection was associated with an increased risk of experiencing Long Covid symptoms (1.53; 95% CI 1.50 to 1.56). However, there was a marked degree of heterogeneity between the studies ( $I^2 = 98\%$ ) (supplement 5-6). At a pooled level according to the COS, individuals with a previous Covid-19 infection were 2.5 times more likely to experience cardiovascular functioning symptoms and conditions (95% CI: 2.16 to 2.96, twice as likely to experience cognitive functioning symptoms and conditions (95% CI: 1.82 to 2.17), and 1.85 times as likely to experience physical functioning symptoms and conditions (95% CI: 1.75 to 1.96).


One study comparing a Covid-19 cohort to an influenza cohort found an association between Covid-19 and long-term effects, indicating the risk of Long Covid, continues to increase 180 days after the illness. [57]

The individual symptoms with the highest relative risk for people with a previous Covid-19 infection compared to controls were olfactory (RR 8.2; 95% CI: 6.85 to 9.81;  $I^2=64\%$ ) and gustatory disturbance (RR 3.93; 95% CI: 3.27 to 4.73;  $I^2=89\%$ ), followed by joint pain (RR 3.44; 95% CI: 2.75 to 4.31) and memory impairments (RR 3.28; 95% CI: 2.70 to 3.97;  $I^2=88\%$ ). Only nasal symptoms showed a significant increased risk for the control population (RR 0.52; 95% CI: 0.43 to 0.63;  $I^2=74\%$ ). Figure 3 presents the relative risk for the range of documented symptoms and signs.

The majority of studies had high heterogeneity with most  $I^2$  values over 60% (supplement 6). The differences between these symptoms, and the heterogeneity within them is likely to be, to some extent, due to other factors (e.g., study settings, populations, and different measurement tools used).

WITHDRAWN  
see manuscript DOI for details

Figure 3: Relative risk of Long Covid signs and symptoms



**Note:** N represents the number of studies per sign and symptom.

Despite small number of studies, we performed subgroup analysis based on setting (hospitalised vs community vs mixed setting). For the majority of symptoms, we find little difference between the three groups, e.g. fatigue, cognitive symptoms, dizziness, gustatory and olfactory disturbances. While for others, including GI symptoms, muscle weakness, and muscle pain we observe higher relative risks among hospitalised patients than those treated in the community (supplement 7).

In addition, sensitivity analysis excluding studies with a high risk of bias showed (no major differences to our results) (supplement 8).

### **Imaging & diagnostics**

Two studies assessed multiorgan dysfunction, including cardiovascular, respiratory, kidney, and liver diseases, showing higher rates in individuals discharged from hospital after Covid-19 compared with the expected risk in the general population [56] and with adults with other respiratory diseases.[59]

Another study found that even for low mortality-risk individuals, organ impairment was more common in individuals after Covid-19 than in healthy controls, with 70% having impairment in one or more organs 4 months after initial symptoms.[54] Similarly, individuals recovering from mild to moderate SARS-CoV-2 infection showed pulmonary, cardiac, thrombotic, and renal dysfunctions without signs of structural brain damage, neurocognitive, or quality-of-life impairment.[53]

Multiple studies assessed pulmonary sequelae and respiratory performance of the population recovered from Covid-19 compared to controls (21.4%, 6/28) [34,47,53,54,56,59]. One study found that at 3 months post-discharge abnormal pulmonary function and residual computer tomography abnormalities were more common in Covid-19 patients, with recovery status varying with disease severity.[47] Similarly, in another study total lung capacity was lower in post-SARS-CoV-2 cases compared with controls while specific airway resistance was significantly higher in patients after SARS-CoV-2 infection than matched controls.[53] Even asymptomatic to mild Covid-19 was shown to be associated with a measurable decline in dynamic lung volumes.[34]

Two studies reported associations between a confirmed prior Covid-19 infection and persisting myocardial involvement, compared to a non-Covid-19 control.[48,55] Another study found evidence of higher sustained endothelial cell activation, coagulation activation, and inflammation between the Covid-19 and control cohorts, but with no difference for macrovascular dysfunction three months after acute Covid-19.[58] One study reported, three months after hospital discharge, right

ventricular function was mildly impaired, likely associated with pulmonary pathology, and diastolic dysfunction was twice as common in Covid-19 patients compared to controls; however, left ventricular dysfunction is not common.[49]

Two studies addressed gastrointestinal complications.[37,45] While one showed a previous Covid-19 infection leads to higher probability of post-infection functional gastrointestinal disorders during a 6-month follow-up compared with the healthy controls [45], another study reported the frequency of irritable bowel syndrome was similar in patients with previous SARS-CoV-2 infection and controls. [37]

## **DISCUSSION**

### *Summary of findings*

This is the second version of our living systematic review, and the first attempt to synthesise the evidence of studies on Long Covid that included control groups. While many reviews continue to confirm a vast range of both physical and neuropsychiatric and/or psychological Long Covid symptoms in community and hospitalised cohorts,[62–64] none have focused on comparing to control populations to estimate the relative risk.[65–67] This new version includes 28 studies reporting on a total of 519,032 individuals in 16 countries. In addition to capturing the breadth of persistent symptoms of Long Covid and confirming their presence in both previously hospitalised and non-hospitalised populations as the first version had shown, this version quantifies the risk of developing these symptoms and complications in comparison to groups of individuals who are not known to have had Covid-19.

Our findings show that people with a confirmed previous SARS-CoV-2 infection are 1.5 times more likely to experience symptoms at 12 or more weeks post-onset when compared to a control group. The core outcomes with the highest relative risk were cardiovascular (RR 2.53 95% CI: 2.16 to 2.96), cognitive (RR 1.99; 95% CI: 1.82 to 2.17), and physical functioning (RR 1.85; 95% CI: 1.75 to 1.96),

highlighting once again the fact that although Covid-19 is a respiratory condition, its long-term symptoms affect multiple parts of the body.

#### *Study strengths and limitations*

This version of the LSR has made significant improvements to cope with the exponentially increasing literature on Long Covid when synthesising the evidence. The collaboration with the EPPI Centre allows us to automate the process of identifying the studies that meet our eligibility criteria in a more efficient and timely manner. This will support more rapid updates of our review in the future. In addition, working closely with the team that has developed the Post-Covid Core Outcomes Set (COS) [14] helped us focus and present results on the symptoms most central to patients, clinicians, and researchers in the area, while remaining aware that over 200 symptoms of Long Covid have been reported.[23]

Despite improvements in the design of the new studies, including longer follow-up periods, more cohorts of patients treated in the community, and studies including children, the literature remains heterogeneous in terms of definition, settings, methods of capturing the presence of Covid-19, symptom ascertainment methods, and types of controls included. In addition, studies included limited details and stratification on pre-existing comorbidities, severity of Covid-19, ethnicity and other characteristics that can help us understand the condition better. This may partly explain the high degree of variability observed.

#### *Methodological considerations*

Our study is the first attempt to synthesise the evidence on Long Covid focusing on studies with controls. Misclassification of cases and controls are an inherent problem for observational epidemiological studies [68], but the problem is particularly challenging for Long Covid research for a number of reasons.[69] The disease (exposure) can be asymptomatic and the diagnostic tests are

not 100% sensitive or specific leading to false negatives and false positives in symptomatic patients and subsequent misclassification. In addition, not everyone seeks, accepts, or has access to tests at all or at the most appropriate time, especially in the community, so the absence of a positive test does not mean that someone has not had Covid-19. Further, infected individuals who do not raise a good antibody response to the coronavirus are more likely to be misclassified as controls than other infected people and this could be important as Long Covid may occur more frequently among such individuals.[70]

Further challenges arise because the disease is changing with different variants emerging with different prevalence of infection at different times (which affects the positive and negative predictive values of tests) and into communities with different levels of immunity from vaccination and prior infections. Moreover, the methods and levels of testing for Covid and its treatment are also evolving and changing. This means that caution must be used when comparing or generalising from different studies.

#### *Research gaps and priorities*

The findings have identified several research gaps and priorities. Although there were more studies identified from Low-Middle-Income Countries, the majority of Long Covid cohorts were conducted in Western Europe. Similarly, despite more studies focusing on children, the evidence is still scant for younger age groups.

Future cohort studies should prioritise including a cohort for comparison. As the pandemic progresses and with the emergence of more transmissible variants, it will become difficult to find control groups that have reliably never been exposed to SARS-CoV2. Hence more studies should compare with historical controls. Meanwhile, to ensure more effective classification of controls, studies should rely on multiple, clearly defined criteria to be classified as a control, including 1) negative PCR results 2) negative antibody test, 3) absence of symptoms suggestive of Covid-19, and

4) consideration of further specialised tests (such as T cell response testing), given the evidence on antibody testing limitations.[70]

There is also a need for research into the role of variants, vaccination, and repeated SARS-CoV2 infection on Long Covid, as none of the studies included in this version focused on this. Studies should also focus on and stratifying results by different potential risk factors.

## **CONCLUSION**

This second version of our living systematic review summarises published evidence on the spectrum of long term Covid-19 associated symptoms and sequelae (as of 22<sup>nd</sup> February 2022). Our findings confirm that exposure to Covid-19 is associated with substantially increased risks of developing long term symptoms and complications beyond the acute phase of the illness. We will continue updating our review periodically, to provide relevant up to date information for clinicians, patients, researchers, policymakers, and health-service commissioners. Version changes will be identified, and previous reports will be archived.

## List of Abbreviations

CI – Confidence interval

COS – Core outcome set

Covid-19 – Coronavirus disease

EHR – Electronic health records

IQR – Interquartile range

ISARIC – International Severe Acute Respiratory and emerging Infection Consortium

LMIC – Low-middle income country

LSR – Living systematic review

NOS – Newcastle-Ottawa Scale

RoB – Risk of bias

RR – Risk ratio

SARS-CoV-2 – Severe Acute Respiratory Syndrome Coronavirus-2

SD – Standard deviation

SWAR - Study within a review

VAS – Visual analogue scale

WHO – World Health Organization

## **DECLARATIONS**

### **Ethics approval and consent to participate.**

Not applicable

### **Consent for publication**

Not applicable

### **Availability of data and materials**

All data generated or analysed during this study are included in this published article and its supplementary files.

### **Competing interest statement**

All authors have completed the ICMJE uniform disclosure form and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years. JCS declares he is an individual living with long-term symptoms of probable Covid-19. All other authors declare no other relationships or activities that could appear to have influenced the submitted work.

### **Funding statement:**

This work was supported by the UK Foreign, Commonwealth and Development Office and Wellcome [215091/Z/18/Z] and the Bill & Melinda Gates Foundation [OPP1209135] and the EU FP7 project PREPARE (602525).

### **Authors contributions:**

MM, CS, VC and LS developed the concept of the study. IS, EH and MM performed the online searches. MM, CS, DTD, IR and DM screened the articles for inclusion. MM, PB, DTD, and CS

extracted data from the included articles. MM, PB, DTD and IR critically appraised the studies. EAS and AB discussed the methodological strengths and limitations of the review, receiving input and suggestions from CH, MO'H, JCS, and DM. CK led on the meta-analysis and presentation of the figures. MM and CS led on the drafting of the manuscript with contributions from all co-authors. All co-authors reviewed and approved the manuscript.

**Acknowledgments:**

We would like to thank the members of the Long Covid support group, and the ISARIC Global Support Centre.

WITHDRAWN  
see manuscript DOI for details

## List of references

- 1 Callard F, Perego E. How and why patients made Long Covid. *Soc Sci Med* 2020;;113426. doi:10.1016/j.socscimed.2020.113426
- 2 Munblit D, O'Hara ME, Akrami A, *et al.* Long COVID: aiming for a consensus. *Lancet Respir Med* 2022;10:632–4. doi:10.1016/S2213-2600(22)00135-7
- 3 WHO. A clinical case definition of post COVID-19 condition by a Delphi consensus. 2021. [https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Post\\_COVID-19\\_condition-Clinical\\_case\\_definition-2021.1](https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1) (accessed 18 Jul 2022).
- 4 Overview | COVID-19 rapid guideline: managing the long-term effects of COVID-19 | Guidance | NICE. <https://www.nice.org.uk/guidance/ng188> (accessed 2 Feb 2021).
- 5 WHO. Coronavirus disease (COVID-19): Post COVID-19 condition. 2021. [https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-\(covid-19\)-post-covid-19-condition](https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition) (accessed 18 Jul 2022).
- 6 ONS. Coronavirus (COVID-19) latest insights: Infections. London: 2022. <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/infections>
- 7 Azzolini E, Levi R, Sarti R, *et al.* Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers. *JAMA* Published Online First: 1 July 2022. doi:10.1001/jama.2022.11691
- 8 Mathieu E, Ritchie H, Ortiz-Ospina E, *et al.* A global database of COVID-19 vaccinations. *Nat Hum Behav* 2021;5:947–53. doi:10.1038/s41562-021-01122-8
- 9 Coronavirus (COVID-19) Vaccinations - Our World in Data. <https://ourworldindata.org/covid-vaccinations> (accessed 10 Aug 2022).
- 10 Chen C, Hauptert SR, Zimmermann L, *et al.* Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. *J Infect Dis* 2022;;jiac136. doi:10.1093/infdis/jiac136
- 11 Michelen M, Manoharan L, Elkheir N, *et al.* Characterising long COVID: a living systematic review. *BMJ Glob Health* 2021;6:e005427. doi:10.1136/bmjgh-2021-005427
- 12 Shemilt I, Michelen M, Stavropoulou C, *et al.* Evaluating the use of a living map and automation tools for updating a living systematic review on long COVID: a study within a review (SWAR).
- 13 Lorenc T, Khouja C, Raine G, *et al.* COVID-19: living map of the evidence. London: : EPPI-Centre, Social Science Research Unit, UCL Social Research Institute, University College London 2020.
- 14 Munblit D, Nicholson T, Akrami A, *et al.* A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study. *Lancet Respir Med* 2022;10:715–24. doi:10.1016/S2213-2600(22)00169-2
- 15 REH-COVER - Rapid living Systematic Reviews. /covid-19/reh-cover-rapid-living-systematic-reviews (accessed 9 Nov 2020).

- 16 Elliott JH, Synnot A, Turner T, *et al.* Living systematic review: 1. Introduction-the why, what, when, and how. *J Clin Epidemiol* 2017;**91**:23–30. doi:10.1016/j.jclinepi.2017.08.010
- 17 Michelen M, Sigfrid L, Manoharan L, *et al.* What are the long-term symptoms and complications of COVID-19: a protocol for a living systematic review. *F1000Research* 2020;**9**:1455. doi:10.12688/f1000research.27284.1
- 18 COVID-19: Living systematic map of the evidence. <https://eppi.ioe.ac.uk/cms/Projects/DepartmentofHealthandSocialCare/Publishedreviews/COVID-19Livingssystematicmapofthevidence/tabid/3765/Default.aspx> (accessed 26 Aug 2022).
- 19 Page MJ, McKenzie JE, Bossuyt PM, *et al.* The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;**372**:n71. doi:10.1136/bmj.n71
- 20 Shemilt I, Arno A, Thomas J, *et al.* Cost-effectiveness of Microsoft Academic Graph with machine learning for automated study identification in a living map of coronavirus disease 2019 (COVID-19) research. *Wellcome Open Res* 2021;**6**.<https://www.google.com/search?client=firefox-b-d&q=Cost-effectiveness+of+Microsoft+Academic+Graph+with+machine+learning+for+automated+study+identification+in+a+living+map+of+coronavirus+disease+2019+%28COVID-19%29+research> (accessed 18 Jul 2022).
- 21 Sterne JAC, Gavaghan D, Egger M. Publication and related bias in meta-analysis: Power of statistical tests and prevalence in the literature. *J Clin Epidemiol* 2000;**53**:1119–29. doi:10.1016/S0895-4356(00)00242-0
- 22 NICE. Long-term effects of coronavirus (long COVID). nhs.uk. 2021.<https://www.nhs.uk/conditions/coronavirus-covid-19/long-term-effects-of-coronavirus-long-covid/> (accessed 26 Aug 2022).
- 23 Davis HE, Assaf GS, McCorkell L, *et al.* Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. *EClinicalMedicine* 2021;**38**:101019. doi:10.1016/j.eclinm.2021.101019
- 24 Nasserie T, Hittle M, Goodman SN. Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19: A Systematic Review. *JAMA Netw Open* 2021;**4**:e2111417. doi:10.1001/jamanetworkopen.2021.11417
- 25 Thomas J, Graziosi S, Brunton J, *et al.* *EPPI-Reviewer: advanced software for systematic reviews, maps and other evidence synthesis [Software]*. 2022. <https://eppi.ioe.ac.uk/CMS/Default.aspx?alias=eppi.ioe.ac.uk/cms/er4>
- 26 Dodd S, Clarke M, Becker L, *et al.* A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery. *J Clin Epidemiol* 2018;**96**:84–92. doi:10.1016/j.jclinepi.2017.12.020
- 27 Munblit D, Buonsenso D, Sigfrid L, *et al.* Post-COVID-19 condition in children: a COS is urgently needed. *Lancet Respir Med* 2022;**10**:628–9. doi:10.1016/S2213-2600(22)00211-9
- 28 Design Science: Bring knowledge to life. Des. Sci. <https://design-science.org.uk/> (accessed 14 Aug 2021).

- 29 Wells GA, Shea B, O'Connell D, *et al.* The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000.
- 30 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;**21**:1539–58. doi:10.1002/sim.1186
- 31 R Core Team. *R: A language and environment for statistical computing*. Vienna, Austria: : R Foundation for Statistical Computing 2021. <https://www.R-project.org/>.
- 32 Long Covid Support Group. Facebook Groups. <https://www.facebook.com/groups/longcovid/> (accessed 29 Oct 2020).
- 33 World Bank Country and Lending Groups – World Bank Data Help Desk. <https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups> (accessed 4 Dec 2020).
- 34 Iversen KK, Afzal S, Ahlström MG, *et al.* Lung Function Decline in Relation to COVID-19 in the General Population: A Matched Cohort Study With Prepandemic Assessment of Lung Function. *J Infect Dis* 2022;**225**:1308–16. doi:10.1093/infdis/jiab636
- 35 Boscolo-Rizzo P, Hummel T, Hopkins C, *et al.* High prevalence of long-term olfactory, gustatory, and chemesthesis dysfunction in post-COVID-19 patients: a matched case-control study with one-year follow-up using a comprehensive psychophysical evaluation. *Rhinology* 2021;**59**:517–27. doi:10.4193/Rhin21.249
- 36 Stallmach A, Kesselmeier M, Bauer M, *et al.* Comparison of fatigue, cognitive dysfunction and psychological disorders in post-COVID patients and patients after sepsis: is there a specific constellation? *Infection* 2022;**50**:661–9. doi:10.1007/s15010-021-01733-3
- 37 Noviello D, Costantino A, Muscatello A, *et al.* Functional gastrointestinal and somatoform symptoms five months after SARS-CoV-2 infection: A controlled cohort study. *Neurogastroenterol Motil Off J Eur Gastrointest Motil Soc* 2022;**34**:e14187. doi:10.1111/nmo.14187
- 38 Riestra-Ayora J, Yanes-Diaz J, Esteban-Sanchez J, *et al.* Long-term follow-up of olfactory and gustatory dysfunction in COVID-19: 6 months case–control study of health workers. *Eur Arch Otorhinolaryngol* 2021;**278**:4831–7. doi:10.1007/s00405-021-06764-y
- 39 Vlaker JH, Wesselius S, Genderen ME van, *et al.* Psychological distress and health-related quality of life in patients after hospitalization during the COVID-19 pandemic: A single-center, observational study. *PLOS ONE* 2021;**16**:e0255774. doi:10.1371/journal.pone.0255774
- 40 Liu Y-H, Wang Y-R, Wang Q-H, *et al.* Post-infection cognitive impairments in a cohort of elderly patients with COVID-19. *Mol Neurodegener* 2021;**16**:48. doi:10.1186/s13024-021-00469-w
- 41 Logue JK, Franko NM, McCulloch DJ, *et al.* Sequelae in Adults at 6 Months After COVID-19 Infection. *JAMA Netw Open* 2021;**4**:e210830. doi:10.1001/jamanetworkopen.2021.0830
- 42 Mattioli F, Stampatori C, Righetti F, *et al.* Neurological and cognitive sequelae of Covid-19: a four month follow-up. *J Neurol* 2021;**268**:4422–8. doi:10.1007/s00415-021-10579-6

- 43 Vaira LA, Salzano G, Le Bon SD, *et al.* Prevalence of Persistent Olfactory Disorders in Patients With COVID-19: A Psychophysical Case-Control Study With 1-Year Follow-up. *Otolaryngol Neck Surg* 2022;**167**:183–6. doi:10.1177/01945998211061511
- 44 Zamora EBC, Romero MM, Sahuquillo MTT, *et al.* Psychological and Functional Impact of COVID-19 in Long-Term Care Facilities: The COVID-A Study. *Am J Geriatr Psychiatry* 2022;**30**:431–43. doi:10.1016/j.jagp.2022.01.007
- 45 Ghoshal UC, Ghoshal U, Rahman MM, *et al.* Post-infection functional gastrointestinal disorders following coronavirus disease-19: A case-control study. *J Gastroenterol Hepatol* 2022;**37**:489–98. doi:10.1111/jgh.15717
- 46 Huang C, Huang L, Wang Y, *et al.* 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *The Lancet* 2021;**397**:220–32. doi:10.1016/S0140-6736(20)32656-8
- 47 Zhou M, Xu J, Liao T, *et al.* Comparison of Residual Pulmonary Abnormalities 3 Months After Discharge in Patients Who Recovered From COVID-19 of Different Severity. *Front Med* 2021;**8**.<https://www.frontiersin.org/articles/10.3389/fmed.2021.682087> (accessed 18 Jul 2022).
- 48 Caiado LDC, Azevedo NC, Azevedo RRC, *et al.* Cardiac involvement in patients recovered from COVID-19 identified using left ventricular longitudinal strain. *J Echocardiogr* 2022;**20**:51–6. doi:10.1007/s12574-021-00555-4
- 49 Ingul CB, Grimsmo J, Mecinaj A, *et al.* Cardiac Dysfunction and Arrhythmias 3 Months After Hospitalization for COVID-19. *J Am Heart Assoc* 2022;**11**:e023473. doi:10.1161/JAHA.121.023473
- 50 Sjøraas A, Bø R, Kalleberg KT, *et al.* Self-reported Memory Problems 8 Months After COVID-19 Infection. *JAMA Netw Open* 2021;**4**:e2118717. doi:10.1001/jamanetworkopen.2021.18717
- 51 Sjøraas A, Kalleberg KT, Dahl JA, *et al.* Persisting symptoms three to eight months after non-hospitalized COVID-19, a prospective cohort study. *PLOS ONE* 2021;**16**:e0256142. doi:10.1371/journal.pone.0256142
- 52 Abd Elnaby H, Hussein MA. Persistent Symptoms of Coronavirus Disease 2019 after Passing Acute Infection. *Med J Cairo Univ* 2021;**89**:2093–101.
- 53 Petersen EL, Goßling A, Adam G, *et al.* Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: The Hamburg City Health Study COVID programme. *Eur Heart J* 2022;**43**:1124–37. doi:10.1093/eurheartj/ehab914
- 54 Dennis A, Wamil M, Alberts J, *et al.* Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. *BMJ Open* 2021;**11**:e048391. doi:10.1136/bmjopen-2020-048391
- 55 Çap M, Bilge Ö, Gündoğan C, *et al.* SPECT myocardial perfusion imaging identifies myocardial ischemia in patients with a history of COVID-19 without coronary artery disease. *Int J Cardiovasc Imaging* 2022;**38**:447–56. doi:10.1007/s10554-021-02477-9
- 56 Ayoubkhani D, Khunti K, Nafilyan V, *et al.* Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. *BMJ* 2021;**372**:n693. doi:10.1136/bmj.n693

- 57 Taquet M, Dercon Q, Luciano S, *et al.* Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. *PLOS Med* 2021;**18**:e1003773. doi:10.1371/journal.pmed.1003773
- 58 Willems LH, Nagy M, ten Cate H, *et al.* Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3 months after COVID-19. *Thromb Res* 2022;**209**:106–14. doi:10.1016/j.thromres.2021.11.027
- 59 Chevinsky JR, Tao G, Lavery AM, *et al.* Late conditions diagnosed 1–4 months following an initial COVID-19 encounter: a matched cohort study using inpatient and outpatient administrative data — United States, March 1–June 30, 2020. *Clin Infect Dis Off Publ Infect Dis Soc Am* 2021;;ciab338. doi:10.1093/cid/ciab338
- 60 Berg SK, Nielsen SD, Nygaard U, *et al.* Long COVID symptoms in SARS-CoV-2-positive adolescents and matched controls (LongCOVIDKidsDK): a national, cross-sectional study. *Lancet Child Adolesc Health* 2022;**6**:240–8. doi:10.1016/S2352-4642(22)00004-9
- 61 Stephenson T, Pereira SMP, Shafran R, *et al.* Physical and mental health 3 months after SARS-CoV-2 infection (long COVID) among adolescents in England (CLoCK): a national matched cohort study. *Lancet Child Adolesc Health* 2022;**6**:230–9. doi:10.1016/S2352-4642(22)00022-0
- 62 Behnood SA, Shafran R, Bennett SD, *et al.* Persistent symptoms following SARS-CoV-2 infection amongst children and young people: A meta-analysis of controlled and uncontrolled studies. *J Infect* 2022;**84**:158–70. doi:10.1016/j.jinf.2021.11.011
- 63 Subramanian A, Nirantharakumar K, Hughes S, *et al.* Symptoms and risk factors for long COVID in non-hospitalized adults. *Nat Med* 2022;;1–9. doi:10.1038/s41591-022-01909-w
- 64 Lopez-Leon S, Wegman-Ostrosky T, Ayuzo del Valle NC, *et al.* Long-COVID in children and adolescents: a systematic review and meta-analyses. *Sci Rep* 2022;**12**:9950. doi:10.1038/s41598-022-13495-5
- 65 Chen X, Laurent S, Onur OA, *et al.* A systematic review of neurological symptoms and complications of COVID-19. *J Neurol* 2021;**268**:392–402. doi:10.1007/s00415-020-10067-3
- 66 Raveendran AV, Jayadevan R, Sashidharan S. Long COVID: An overview. *Diabetes Metab Syndr* 2021;**15**:869–75. doi:10.1016/j.dsx.2021.04.007
- 67 Fernández-de-las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V, *et al.* Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: A systematic review and meta-analysis. *Eur J Intern Med* 2021;**92**:55–70. doi:10.1016/j.ejim.2021.06.009
- 68 Copeland KT, Checkoway H, McMichael AJ, *et al.* Bias due to misclassification in the estimation of relative risk. *Am J Epidemiol* 1977;**105**:488–95.
- 69 Long Covid: Issues around control selection. By Nisreen Alwan. <https://www.longcovidkids.org/post/long-covid-issues-around-control-selection-by-nisreen-alwan> (accessed 10 Aug 2022).
- 70 Krishna BA, Lim EY, Mactavous L, *et al.* Evidence of previous SARS-CoV-2 infection in seronegative patients with long COVID. *eBioMedicine* 2022;**81**. doi:10.1016/j.ebiom.2022.104129

**WITHDRAWN**  
see manuscript DOI for details